NHS-Galleri: design of the largest randomised trial of a multi-cancer blood test
The NHS-Galleri design paper is the protocol for a 140,000-person randomised trial in England testing whether three annual Galleri blood tests reduce late-stage (III-IV) cancer diagnoses, the first MCED trial powered for a stage-shift endpoint.
NHS-Galleri (ISRCTN91431511) enrolled about 140,000 asymptomatic adults aged 50-77 through NHS England, randomised 1:1 to annual Galleri testing for three years with results returned, or to blood draws stored without testing. The design paper set out the primary endpoint of a reduction in stage III-IV cancer incidence between arms, with secondary endpoints including stage IV incidence, cancer-specific mortality and test performance.
The trial deliberately over-sampled deprived and ethnically diverse communities using mobile clinics. Results were reported in 2026; the trial record in this corpus tracks the primary and secondary outcomes and the regulatory response.
The design is important in its own right: it established stage shift as a pragmatic proxy endpoint for screening trials of multi-cancer tests, a choice that remains contested.
- About 140,000 participants randomised, recruited through mobile clinics across NHS regions in England
- Primary endpoint: absolute reduction in stage III-IV cancers in the intervention arm; key secondary endpoint: stage IV incidence
- Test results were not returned in the control arm, preserving blinding of the population and clinicians
- Population enriched for deprived and minority communities, unusual for a screening trial
NHS-Galleri is the trial that will decide whether a blood test for many cancers at once should be offered by a health system. Its endpoint is a reduction in late-stage cancer rather than deaths, so even a positive result leaves the mortality question to be settled by longer follow-up.
- Stage shift is a surrogate: fewer late-stage cancers does not guarantee fewer deaths, and lead-time and overdiagnosis can distort it
- Three annual rounds is short for detecting slow-growing cancers
- A single commercial test; results may not generalise to other MCED assays
- Sponsor involvement in design and analysis (GRAIL) was substantial
Pages like this
not linked directly; found by shared links- IdeaA whole-population cancer interception programme: risk-stratify every adult, detect and intercept early
Shares PATHFINDER 2, NHS-Galleri, Galleri, Positive predictive value (PPV).
- Key paperPATHFINDER: the first prospective test of a multi-cancer blood test in people without symptoms
Shares PATHFINDER 2, NHS-Galleri, Galleri, Positive predictive value (PPV).
- IdeaOpen-source models that translate stage shift into lives saved, for every cancer
Shares NHS-Galleri, Stage shift, Most lethal cancers are found late, Trial design, endpoints and cost.
- IdeaMulti-cancer blood test as the first step for patients with non-specific symptoms
Shares Galleri, Positive predictive value (PPV), Multi-cancer early detection (MCED), Most lethal cancers are found late.
- IdeaPre-agreed update rules so an MCED test is not obsolete when its trial reads out
Shares PATHFINDER 2, NHS-Galleri, Multi-cancer early detection (MCED), Most lethal cancers are found late.
- Key paperDETECT-A: a blood test plus PET-CT found treatable cancers in 10,000 women with no symptoms
Shares Positive predictive value (PPV), Stage shift, Multi-cancer early detection (MCED), Overdiagnosis and false alarms.
- IdeaBlood-based pancreatic cancer detection in new-onset diabetes
Shares Galleri, Positive predictive value (PPV), Multi-cancer early detection (MCED), Most lethal cancers are found late.
- IdeaA urine DNA test to decide who with blood in the urine needs a camera test
Shares Positive predictive value (PPV), Overdiagnosis and false alarms, Most lethal cancers are found late, Liquid biopsy (ctDNA).